Still’s disease, a systemic inflammatory condition historically categorized under adult-onset systemic juvenile idiopathic arthritis, is characterized by quotidian fevers, rash, and joint inflammation. These clinical hallmarks are thought to arise from dysregulated immune responses, involving cytokine storms and aberrant activation of innate immune cells. However, many adult patients present with a perplexing symptom constellation indicative of autoinflammation but lack definitive diagnostic criteria, leaving clinicians grappling with ambiguity and often resorting to empirical treatment strategies.

The investigative team embarked on an extensive immunophenotyping journey, employing advanced techniques such as multi-parameter flow cytometry, transcriptomic analyses, and cytokine profiling to delineate the immune architecture of these patients with enigmatic autoinflammatory features. The results were striking: although the patients did not meet formal clinical criteria for Still’s disease, their immune cell profiles revealed formidable parallels. Specifically, elevated levels of proinflammatory cytokines—including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)—were detected, consistent with the inflammatory milieu characteristic of Still’s disease.

Moreover, the study underscored the aberrant activation of innate immune components, particularly monocytes and neutrophils, which appeared to orchestrate a sustained inflammatory cascade. These myeloid cells exhibited transcriptional programs reminiscent of those in Still’s disease, highlighting a shared pathophysiological axis. This convergence of immune signatures suggests that the wider spectrum of autoinflammation may encompass subsets previously categorized as idiopathic but now attributable to discrete immunological phenotypes.

One of the particularly intriguing facets of this research lies in its potential to transform diagnostic paradigms. By applying immunological benchmarks derived from Still’s disease to patients with nebulous inflammatory symptoms, clinicians may achieve earlier, more accurate diagnoses. The capacity to identify phenocopies—patients who mirror the immune perturbations of Still’s disease without fully fulfilling its clinical criteria—could revolutionize therapeutic decision-making and patient outcomes.

Crucially, the study reinforces the notion that autoinflammatory diseases, while clinically heterogeneous, share common immunological denominators that transcend traditional disease boundaries. This immunological commonality paves the way for stratified medicine approaches, wherein treatments targeting specific cytokines or immune pathways can be tailored to patients based on their molecular immune signatures rather than solely on phenotypic presentations.

Therapeutically, the implications are profound. The identification of IL-1 and IL-6 dysregulation in these phenocopy patients spotlights the potential efficacy of biologic agents such as anakinra or tocilizumab—already approved for Still’s disease—in this broader patient population. Such targeted therapies could mitigate systemic inflammation, alleviate symptoms, and improve quality of life, circumventing the need for generalized immunosuppression with its attendant risks.

Further elucidation of the underlying genetics of these patients may deepen our understanding of disease susceptibility and progression. While Still’s disease itself lacks definitive genetic markers, this research invites inquiry into whether shared genomic variants or epigenetic modifications predispose individuals to autoinflammation that manifests along a Still’s disease-like immune trajectory.

In addition to patient-focused clinical benefits, the study provides a compelling model for exploring the interplay between innate immunity and systemic autoinflammation. By dissecting the transcriptional networks active in affected myeloid cells, the researchers have identified candidate molecular drivers and regulatory nodes that could serve as novel drug targets. This molecular insight is invaluable as the field increasingly moves from symptomatic treatment toward precision immunotherapy.

The methodological rigor exhibited in this investigation is notable. Cutting-edge single-cell RNA sequencing permitted the characterization of immune cell heterogeneity at an unprecedented resolution, delineating subtle differences and commonalities between classic Still’s disease and phenocopies. This granular analysis revealed unique subpopulations of immune cells whose activation states correlate with disease severity and clinical manifestations, opening avenues for biomarker development.

In terms of epidemiological impact, recognizing that a subset of autoinflammatory patients phenocopy Still’s disease expands the estimated burden of these clinically challenging disorders. Heightened awareness can prompt epidemiologists to reassess prevalence data and encourage the inclusion of immune profiling in population-level studies, enhancing the accuracy of disease mapping and resource allocation.

Beyond direct clinical and scientific implications, this research also poses intriguing questions about the nature of disease classification. The immune system’s complexity and plasticity suggest that rigid disease categories may be insufficient to capture the continuum of pathogenic mechanisms at play. Instead, the concept of immunophenotypic spectra or overlap syndromes emerges, calling for an integrative approach that bridges clinical presentation, immunobiology, and genetics.

As the research community digests these findings, collaborative efforts will be essential to replicate and expand upon the conclusions. Longitudinal studies tracking patient cohorts over time can illuminate the natural history and therapeutic responses of these phenocopy individuals, providing a comprehensive picture of disease evolution. Additionally, integrating environmental and lifestyle factors may shed light on triggers that precipitate or modulate the autoinflammatory process.

Patient advocacy and education will also benefit from these revelations. Empowering patients with knowledge about their immune profiles can enhance engagement in personalized care plans and foster a proactive approach to disease management. Moreover, recognizing phenocopies reinforces the importance of nuanced diagnostic evaluation, reducing the stigma and frustration often associated with undiagnosed inflammatory syndromes.

In conclusion, the study by Veiga and colleagues marks a pivotal step forward in decoding the enigmatic realm of adult autoinflammation. By revealing that patients with autoinflammation of unknown origin partially phenocopy the immune presentation of Still’s disease, the research bridges gaps between clinical ambiguity and immunological clarity. This convergence not only heralds improved diagnostic accuracy and targeted therapeutic strategies but also encourages a paradigm shift toward a more holistic and mechanistic understanding of autoinflammatory diseases. As the field advances, the integration of advanced immunophenotyping technologies, molecular biology, and clinical acumen will undoubtedly transform patient care and inspire innovative interventions in systemic inflammatory disorders.

Subject of Research: Adult patients with autoinflammation of unknown origin and their immunological similarities to Still’s disease.

Article Title: Adult patients with autoinflammation of unknown origin partially phenocopy the immune presentation of Still’s disease.

Article References: Veiga, R., De Vuyst, L., Poulet, C. et al. Adult patients with autoinflammation of unknown origin partially phenocopy the immune presentation of Still’s disease. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70895-1

Image Credits: AI Generated

RB-1355 is distinguished by its unique mechanism of action which centers on the use of a patient’s own macrophages, a type of immune cell often residing in the tumor milieu. These macrophages are extracted and then subjected to an ex vivo hyperactivation process using proprietary methodologies designed to induce a robust pro-inflammatory and immune-supportive phenotype. This reprogramming effectively converts macrophages from potentially tumor-promoting actors to powerful anti-tumor effectors. Upon reintroduction into the patient’s lesions via direct intratumoral injections, these engineered macrophages reshape the tumor microenvironment by igniting a cascade of immune responses that encompass activation of neoantigen-specific T cells and B cells, thereby orchestrating a comprehensive immune assault on lymphoma cells.

One of the most compelling advantages of RB-1355 therapy is the rapid manufacturing pipeline, which allows for treatment readiness in approximately one week. This expedited timeline stands in stark contrast to other cell therapies which often require extended preparation periods, thereby making RB-1355 a more accessible option that can be deployed in a timely manner. Additionally, the therapy circumvents the need for lymphodepleting chemotherapy, a common preconditioning regimen that can cause considerable toxicity. This attribute not only enhances safety but also broadens the eligibility of patients who can receive the therapy irrespective of tumor mutational status, positioning RB-1355 as a versatile therapeutic across a spectrum of B-cell and T-cell lymphomas.

The initial clinical findings have been presented at the prestigious 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), showcasing promising efficacy signals. Among thirteen heavily pretreated patients enrolled in the trial, two individuals with diffuse large B-cell lymphoma (DLBCL) achieved complete remission, notably including those who had previously failed CAR T cell therapy—a population with extremely limited treatment options. These responses, including durability beyond 100 days for one patient, underscore the potential of RB-1355 to address aggressive, refractory disease in a clinical setting.

In addition to complete remissions, partial responses were also observed in patients suffering from peripheral T-cell lymphoma and mycosis fungoides, malignancies traditionally resistant to standard therapies. This breadth of activity exemplifies RB-1355’s capacity to generate meaningful clinical benefit across heterogeneous lymphoma subtypes. Equally important is the favorable safety profile reported from the trial; no dose-limiting toxicities were encountered, and only three instances of low-grade adverse effects were noted, indicating that RB-1355 is not only efficacious but also well tolerated in a fragile patient population with limited alternatives.

From an immunological standpoint, the macrophage-centric approach of RB-1355 leverages the plasticity of these myeloid cells to break the immune tolerance often established in the tumor microenvironment. By instigating an inflammatory cascade, it promotes antigen presentation and stimulates both innate and adaptive immune components. This dual activation is critical for achieving sustained anti-lymphoma activity, given the complex immune evasion strategies employed by malignant lymphocytes. Furthermore, this method does not depend on the presence of specific actionable mutations in the lymphoma cells, enabling a broad-spectrum therapeutic effect that could redefine treatment algorithms for refractory lymphomas.

The potential implications for patients are profound. Historically, relapsed and refractory non-Hodgkin lymphoma cases have represented a therapeutic dead-end with limited durable options. RB-1355’s promising early results suggest it could fill this unmet need by offering a new avenue for disease control, especially for those who have exhausted conventional chemotherapy, targeted agents, and even advanced therapies like CAR T cells. The rapid preparation and administration of RB-1355 could also minimize delays in treatment initiation, a critical factor in managing aggressive lymphomas.

Current ongoing investigations aim to optimize RB-1355 through dose escalation and repeated treatment cycles to enhance the durability of responses and potentially increase remission rates. Researchers are also exploring synergistic combinations with other immunomodulatory agents to further amplify anti-lymphoma immunity. As the body of evidence grows, RB-1355 may represent the next frontier in cell therapy by expanding the types of immune cells engineered and by circumventing the limitations associated with existing therapies that primarily target T cells.

Moreover, the development of RB-1355 reflects a growing appreciation in oncology of the tumor microenvironment’s role in cancer progression and response to therapy. Unlike approaches that solely target malignant cells, therapies like RB-1355 aim to re-educate the immune ecosystem surrounding the tumor, creating an inhospitable environment for cancer cell survival. Such strategies could herald a new class of treatments for hematologic malignancies and potentially solid tumors, enabling a more holistic immune-based eradication of cancer.

The involvement of BobcatBio in supporting this research illustrates the critical importance of collaboration between academic institutions and biotechnology enterprises in translating cutting-edge science into clinical realities. The rapid translation from bench to bedside exemplifies how innovations in cellular manufacturing and immune engineering can swiftly impact patient care in fields where therapeutic needs remain urgent.

In conclusion, RB-1355 represents an innovative and promising cell therapy that reshapes the landscape of non-Hodgkin lymphoma treatment by utilizing hyperactivated macrophages to generate a multi-dimensional immune response without the need for conventional preconditioning regimens. Early clinical data show encouraging safety and efficacy profiles in patients with relapsed or refractory disease, including those unresponsive to CAR T therapies. Continued clinical development will delineate its role within the expanding arsenal against aggressive lymphomas, potentially offering hope to a patient population with critical unmet needs.

Subject of Research: Novel cell therapy RB-1355 for relapsed and refractory non-Hodgkin lymphoma

Article Title: RB-1355: A Macrophage-Based Cell Therapy Revolutionizing Treatment of Refractory Non-Hodgkin Lymphomas

News Publication Date: 2026 (Date of presentation at ASTCT/CIBMTR 2026 Tandem Meetings)

Web References:

• MD Anderson Non-Hodgkin Lymphoma Overview: https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma.html
• CAR T Cell Therapy at MD Anderson: https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html
• Paolo Strati, M.D. Profile: https://faculty.mdanderson.org/profiles/paolo_strati.html
• ASTCT/CIBMTR Tandem Meetings 2026 Program: https://www.tandemmeetings.com/
• Full Abstract: https://tandem.virtual-meeting.org/programme/presentation/677607

Keywords:
Cell therapies, macrophage immunotherapy, non-Hodgkin lymphoma, relapsed lymphoma, refractory lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, tumor microenvironment, immunotherapy, RB-1355, novel cancer treatments